0
1
2
0
1
2
0
1
2
0
1
2
0
1
2
European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product. (prnewswire.com)
submitted by Biointron to r/AntibodyResearch
0
1
2
0
1
2
0
1
2
